NCT01895309View on ClinicalTrials.gov

A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

596

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

October 31, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Enbrel (etanercept)

DRUG

SB4 (proposed biosimilar to etanercept)

Trial Locations (2)

Unknown

Investigational Site, Kielce

Investigational Site, Southampton

All Listed Sponsors

lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT01895309 - A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy | Biotech Hunter | Biotech Hunter